ABIVAX | Sustainability Performance
Develops obefazimod and other therapies for chronic inflammatory diseases.
2013
France
51 - 200 employees
Biotechnology
$1M - 10M in revenue
N/A in profitability
Sustainability Ranking & Industry Benchmark
#7378
Overall#393
in France#152
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and exclusionsFinancial Data
Business performanceCapital & innovation
Market cap
Revenue
R&D intensity
Market cap
Revenue
EBITDA
Operating margin
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
-%FY2025
R&D as % of revenue
R&D as % of revenue
Industry benchmark
Powered by illuminem
Return on invested capital
-69.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Not available
17%
Independent Directors
4 out of 24 incl. management
Overall score
0
Environment
0
Social
0
Governance
0
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Not available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
Reporting
Not reporting on Sustainability
Not committed to key sustainability initiatives